-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

722A.O2.6 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD

Symposia: Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Acute Myeloid Malignancies, Translational Research, Drug development, Clinical Practice (Health Services and Quality), Clinical Research, GVHD, Diseases, Immune Disorders, Treatment Considerations, Adverse Events, Computational biology, Myeloid Malignancies, Technology and Procedures, Study Population, Human
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Ballroom 20CD (San Diego Convention Center)
Moderators:
Albert C Yeh, MD, and Hannah Choe, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital
Disclosures:
No relevant conflicts of interest to declare.
9:30 AM

Yanmin Zhao, MD1,2,3*, Yi Luo2,3,4, Jimin Shi1,2,3*, Shunqing Wang5*, Caixia Wang5*, Erlie Jiang6, Chen Liang7*, Xiaoyu Zhu8, Xuejun Zhang9*, Fankai Meng10*, Hua Jin11*, Yeqian Zhao2,3,12*, Jian Yu, MD1,2,3*, Xiaoyu Lai, MD2,3,12*, Lizhen Liu2,3,12*, Huarui Fu, MD1,2,3*, Yishan Ye, MD1,2,3*, Congxiao Zhang, MD2,3,13*, Tao Wang14*, Lifan Tu15*, Xunqiang Wang16* and He Huang, MD2,3,17*

1Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
2Institute of Hematology, Zhejiang University, Hangzhou, China
3Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
4Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Bone Marrow Transplantation, the First Affiliated Hospital of Zhejiang Universit, Hangzhou, China
5Department of Hematology, Guangzhou First People's Hospital, Guangzhou, China
6Department of Hematology, Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
7Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
9Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
10Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China
12Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
13Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14Department of Clinical Biostatistics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China
15Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, AL, China
16Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China
17Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, hangzhou, China

9:45 AM

Hannah Choe, MD1, Amandeep Salhotra, MD2, Nosha Farhadfar, MD3*, Mi Kwon4*, Britnie Thomas, PhD5*, Vedran Radojcic6*, Chuan Tian5*, Shuyuan Lou5*, Daniel Wolff, MD7* and Stephanie J. Lee8*

1Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, OH
2Hematology and HCT, City of Hope National Medical Center, Duarte, CA
3Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, TX
4Hospital General Universidad Gregorio Marañon, Madrid, Spain
5Incyte Corporation, Wilmington, DE
6Syndax Pharmaceuticals, Inc., Waltham, MA
7Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Bonn, Germany
8Fred Hutchinson Cancer Center, Seattle, WA

10:00 AM

Xiaodong Mo1*, He Huang, MD2*, Feng Chen3*, Yi Luo2, Jia Chen3*, Erlie Jiang4, Yicheng Zhang5*, Linghui Xia6*, Chengwei Luo Luo, M.D.7*, Xinchuan Chen, MD, PhD8*, Nainong Li, MD, PhD9, Ming Jiang10*, Sujun Gao11*, Dongqin Yang12*, Qingli Zuo12*, Yimin Chen12*, Li Yao12*, Pan Liang12* and Depei Wu, MD, PhD3

1Peking University Institute of Hematology, Peking University Peoples’ Hospital, Beijing, China
2Bone marrow transplantation department, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
3Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
4Department of Hematology, Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
5Department of hematopathology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
8Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
9Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
10Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
11Department of Hematology, The First Hospital of Jilin University, Changchun, China
12Abbisko Therapeutics Co, Ltd, Shanghai, China

10:15 AM

Robert Zeiser, MD1,2,3,4, Hannah Choe, MD5, Holger Adelmann, MD, PhD6*, Nader N. Youssef, MD, MBA7*, Anastasia Eremeeva6*, François Collin6* and Yi-Bin Chen, MD, MS8

1German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany
2Comprehensive Cancer Center Freiburg (CCCF), Medical Center – University of Freiburg, Freiburg, Germany
3Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
4Center for Integrative Biological Signaling Studies (BIOSS and CIBSS), University of Freiburg, Freiburg im Breisgau, Germany
5Blood and Marrow Transplantation Program, James Cancer Hospital, The Ohio State University, Columbus, OH
6Ironwood Pharmaceuticals, Inc., Basel, Switzerland
7Ironwood Pharmaceuticals, Inc., Boston
8Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA

10:30 AM

Zengkai Pan, MD, PhD1*, Yujun Deng, M.S.2*, Jingtao Huang3*, Aijie Huang, MD4*, Xiong Ni, MD, PhD5*, Lei Gao, MD, PhD6*, Chuanhe Jiang, MD, PhD7*, Luxiang Wang, MD, PhD7*, Zilu Zhang, MD, PhD7*, Quan Gu, PhD8*, Hui Cheng9*, Jianmin Wang, MD, PhD10, Hongbo Hu, PhD11* and Xiaoxia Hu7*

1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Center for Hematology and Immunology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, CHN
3Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Nati, Shanghai, China
4The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Shanghai, China
5Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, CHN
6Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China
7Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, tianjin, China
9State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
10Changhai Hospital, Shanghai, China
11Center For Hematology and Immunology, State Key Laboratory of Biotherapy, West C, Chengdu, CHN

10:45 AM

Nicoletta Cieri, MD, PhD1,2,3, Yiren Shao4*, Kaila Power2*, Vincent T. Ho, MD2,3*, Jonathan Stevens5*, William J. Lane5*, Haesook T. Kim, PhD4, Donna S. Neuberg, ScD4, Chip Stewart, PhD1*, Gad Getz, PhD1,3,6*, Jerome Ritz, MD2,3, Robert J. Soiffer, MD2,3 and Catherine J. Wu, MD1,2,3*

1Broad Institute of MIT and Harvard, Cambridge, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Harvard Medical School, Boston, MA
4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
5Brigham and Women's Hospital, Boston, MA
6Department of Pathology, Massachusetts General Hospital, Boston, MA

*signifies non-member of ASH